ReFaC hires Dr Virginia Gretton as technical officer

Has experience with all aspects of REACH registration

Dr Virginia Gretton has joined ReFaC, the REACH Facilitiation Company based in Crewe, Cheshire, UK, as technical officer.

Gretton was formerly regulatory manager at Harlan Laboratories, Derbyshire, where she was involved with all aspects of REACH registration and compliance. This covered data gap analysis, testing plans, exposure scenarios, risk assessment, classification and labelling, downstream user interaction, Safety Data Sheet preparation, as well as post-registration support.

In addition, Dr Gretton has held posts in academia and managed clinical research projects. She holds a DPhil in chemistry from the University of York, a BSc in combined science, and a post-graduate certificate in REACH management.

Peter Newport, ReFaC’s company secretary, said: ‘Virginia brings a wealth of practical regulatory experience, skills and technical knowledge to her new role, which will be invaluable in helping and advising clients on all aspects of REACH compliance.’

You may also like

Regulatory

Amcor’s Winterbourne site achieves ISO 13485 certification, strengthening its position and capabilities in healthcare

ISO 13485:2016 is an internationally recognised quality management standard specifically for medical devices.
Regulatory

Roche wins CE mark for first blood-based immunoassay to identify ApoE4 Alzheimer's risk variant

Roche's Elecsys ApoE4 test has received CE mark approval as the first in-vitro diagnostic immunoassay to detect the ApoE4 genetic variant from a simple blood sample, potentially eliminating the need for confirmatory DNA testing in Alzheimer's patients who do not carry the variant
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Regulatory

Shilpa Biologicals and mAbTree secure FDA Orphan Drug Designation for rare blood cancer biologic

The FDA has granted Orphan Drug Designation to the pair's investigational monoclonal antibody for Essential Thrombocythemia and Polycythemia Vera, two rare chronic blood cancers with significant unmet treatment need
Media

CBA releases statement welcoming government's decision to incude biocides in post-Brexit negotiations

Biocides have now been officially included in the scope of negotiations, which the association has called an "important and practical step towards cutting red tape and restoring clarity for businesses," though the "reality is that much more still needs to be done"
Manufacturing

Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™

Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia
Regulatory

Orbia Fluor & Energy Materials registers US DMF file for low-GWP propellant

The fluor-based product manufacturer announced the creation of a US Type IV Drug Master File (DMF) for the low-GWP excipient Zephex 152a, with pharma companies now able to reference the data package for faster, lower-risk FDA reviews for pMDIs
Subscribe now